archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • News Archive
    Contact CSL Home Newsroom News Archive CSL Receives FTC Request for Additional Information CSL Receives FTC Request for Additional Information Melbourne Australia 13 10 2008 CSL Receives FTC Request for Additional Information on its Proposed Merger with Talecris Biotherapeutics CSL Limited today announced that it has received a request for additional information commonly referred to as a Second Request from the U S Federal Trade Commission FTC regarding its proposed

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1221487209028/prdetail.htm (2014-01-05)
    Open archived version from archive


  • News Archive
    CSL Appoints New Director Melbourne Australia 02 09 2008 CSL today announced that Mr David Anstice has been appointed a Director of the Company effective 2 September 2008 Mr Anstice was a senior executive of Merck Co Inc for many years retiring as 1 September 2008 Mr Anstice served as President of Merck Human Health for the US Canada Europe Japan and Asia in separate assignment He has also been

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1219872134045/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive Full Year Results for 2008 Full Year Results for 2008 Melbourne Australia 13 08 2008 CSL Limited today announced its operating results for the full year ended 30 June 2008 Download the full release Full

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1218118041988/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    of Unsolicited Share Offers CSL Limited Warns Shareholders of Unsolicited Share Offers Melbourne Australia 10 02 2008 CSL Limited has become aware of unsolicited offers to shareholders to purchase their shares for a price which significantly undervalues their holding CSL has advised shareholders on receipt of such an offer that they check it carefully CSL urges shareholders to speak with their broker or financial advisor for advice if they are

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1199979263555/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Search Results
    Luxembourg Brazil Canada China Denmark France Germany Italy Japan Mexico Netherlands Nordic Spain Switzerland UK USA CSL Plasma US CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=200&dropXSL=yes (2014-01-05)
    Open archived version from archive

  • CSL Bioplasma
    s national fractionator of plasma derived therapeutics since 1952 Today Australian Governments continue to choose CSL Biotherapies as Australia s national plasma fractionator Regulated by the Therapeutic Goods Administration a regulator held in high regard worldwide CSL Biotherapies and the Australian Red Cross Blood Service ensure that the blood and plasma donations made voluntarily by people living in Australia continue to deliver the benefits that self sufficiency provides These benefits include a sustainable reliable and high quality source of plasma derived therapeutics developed to treat serious medical conditions including immunodeficiency disorders a range of haematological and neurological disorders haemophilia haemolytic disease of the newborn and trauma A range of products is also available to provide protection against infectious diseases including hepatitis B tetanus chickenpox and cytomegalovirus With more than 50 years experience fractionating plasma derived therapeutics and strengths in innovation quality and safety CSL Biotherapies has also been chosen as the national plasma fractionator by New Zealand Hong Kong Malaysia Singapore and Taiwan CSL Biotherapies works with health authorities and blood services in these countries to ensure they experience the benefits that self sufficiency in plasma derived therapeutics provides These benefits include peace of mind regarding the quality safety cost

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1195505488297/content/1195505488062/content.htm (2014-01-05)
    Open archived version from archive